Neurocrine Biosciences (NBIX) EBIT (2010 - 2026)

Neurocrine Biosciences has reported EBIT for 17 years, with the latest figure at $193.4 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT rose 719.49% year-over-year to $193.4 million; the trailing twelve-month figure through Mar 2026 stood at $788.9 million (up 59.44% YoY), and the FY2025 full-year result was $619.1 million, up 8.52% from the prior year.
• EBIT for Q1 2026 stood at $193.4 million, down from $210.9 million in the prior quarter.
• The five-year high for EBIT was $239.0 million in Q3 2025, with the low at -$114.2 million in Q1 2023.
• Historically, EBIT has averaged $110.8 million across 5 years, with a median of $141.2 million in 2023.
• Annual changes were most pronounced in 2023 — EBIT tumbled 3783.87% — and 2026, when it jumped 719.49%.
• Neurocrine Biosciences' EBIT stood at $103.4 million in 2022, then soared by 45.36% to $150.3 million in 2023, then fell by 5.52% to $142.0 million in 2024, then soared by 48.52% to $210.9 million in 2025, then decreased by 8.3% to $193.4 million in 2026.
• The last three EBIT figures came in at $193.4 million (Q1 2026), $210.9 million (Q4 2025), and $239.0 million (Q3 2025), per Business Quant data.